Table 1.
Characteristics
| Variable | No anticancer treatment last 30 days n = 174 | Anticancer treatment given last 30 days n = 73 | P value a | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Age (years) - median (min - max) | 72 | (18–93) | 74 | (40–91) | NS |
| Length of stay (days) - median (min - max) | 8 | (0–84) | 12 | (0–68) | 0.03 |
| Gender | NS | ||||
| Female | 68 | 39% | 28 | 38% | |
| Male | 106 | 61% | 45 | 62% | |
| Hospital | < 0.01 | ||||
| District Hospital Lofoten | 27 | 16% | 6 | 8% | |
| District Hospital Vesterålen | 47 | 27% | 11 | 15% | |
| Central Hospital Bodø | 100 | 57% | 56 | 77% | |
| Department | NS | ||||
| Internal medicine | 76 | 44% | 44 | 60% | |
| Surgery | 91 | 52% | 25 | 34% | |
| Others | 7 | 4% | 4 | 6% | |
| Primary malignancy | 0.02 | ||||
| Upper gastrointestinal | 34 | 20% | 5 | 7% | |
| Colorectal | 27 | 15% | 4 | 5% | |
| Lung | 38 | 22% | 21 | 29% | |
| Breast | 7 | 4% | 4 | 5% | |
| Gynaecological | 5 | 3% | 2 | 3% | |
| Urological | 8 | 5% | 6 | 8% | |
| Male genitalia | 11 | 6% | 4 | 5% | |
| Haematological and lymphoma | 17 | 10% | 22 | 30% | |
| Unknown origin | 15 | 8% | 2 | 3% | |
| Other b | 12 | 7% | 3 | 4% | |
| Treatment intent | < 0.001 | ||||
| Palliative | 135 | 78% | 67 | 92% | |
| Curative | 2 | 1% | 3 | 4% | |
| Diagnostic | 37 | 21% | 3 | 4% | |
| Anticancer treatment | < 0.001 | ||||
| Systemic treatment | 64 | 37% | 52 | 71% | |
| Radiotherapy | 5 | 3% | 14 | 19% | |
| Surgery | 5 | 3% | 7 | 10% | |
| No treatment | 100 | 57% | 0 | 0% | |
| Specialist palliative care | NS | ||||
| > 30 days before death | 33 | 19% | 11 | 15% | |
| < 30 days before death | 32 | 18% | 14 | 19% | |
| Not involved | 109 | 63% | 48 | 66% | |
aThe p value measures the difference between the two groups and was set to 0.05. NS not significant
bThe group consist of patients with cancer from head-neck, sarcoma, malignant melanoma, eye and CNS